CG Oncology, Inc. (CGON)
NASDAQ:CGON
Want to see CGON full AI Analyst Report?
CGON Stock Chart & Stats
$73.43
-$0.55(-1.77%)
At close: 4:00 PM EST
$73.43
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$23.65 - $75.50
Previous Close$30.46
Volume740.02K
Average Volume (3M)1.01M
Market Cap
$5.80B
Enterprise Value$5.30B
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$7.58M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 07, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding88,202,480
10 Day Avg. Volume1,019,884
30 Day Avg. Volume1,007,644
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue1.05K
Enterprise Value/Gross Profit-157.33
Enterprise Value/Ebitda-28.75
Forecast
1Y Price Target
$91.55Price Target Upside24.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.72
Revenue Forecast (FY)$11.76M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Equity BaseA very large equity base and negligible debt provide durable financial flexibility to fund multi-year clinical programs, R&D and potential commercialization. This reduces refinancing and bankruptcy risk, supports strategic optionality (partnerships, acquisitions, trial spend) as milestones are pursued.
Appointment Of Seasoned Biotech CFOInstalling an experienced biotech CFO with prior public and commercial-stage experience materially strengthens financial planning, capital markets access and commercialization preparation. Performance equity tied to cash-flow and commercialization aligns incentives with long-term execution and fiscal discipline.
Positive Revenue Growth MomentumSustained top-line growth, even from a small base, signals improving commercialization or program progress and validates demand/trial uptake trends. Continued revenue momentum, if sustained, can progressively offset development spend and underpin scaling opportunities post-approval.
Bears Say
High And Rising Cash BurnSubstantial negative operating and free cash flows that have widened year-over-year create persistent funding pressure. Continued burn requires external financing or rapid revenue ramp, increasing dilution risk and placing strategic constraints on trial pacing and commercialization investments over the next several quarters.
Negative Gross Profit And Widening LossesNegative gross margins and accelerating operating losses reflect a cost structure far above current revenue and indicate long lead times to profitability. This persistent unprofitability pressures future margins and requires large scale or cost restructuring to achieve sustainable earnings once commercial activities expand.
No Recurring Commercial Revenue; Financing DependentAbsence of recurring product revenue means the company is structurally reliant on capital markets or deals to fund operations. This reliance raises execution risk if markets tighten or milestones slip, likely resulting in dilution or constrained program timelines until consistent commercial cash flows emerge.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $23.65 and its highest was $75.50 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $5.80B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 43 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on May 08, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.556 by -$0.154.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.66.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 88,202,480 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.556. Following the earnings report the stock price went up 0.636%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.55 (24.67% Upside)
$91.55 (24.67% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Positive
20 days / 200 days
Momentum
156.15%
12-Months-Change
Fundamentals
Return on Equity
-23.33%
Trailing 12-Months
Asset Growth
55.90%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
CGON Stock 12 Month Forecast
Average Price Target
$91.55
▲(24.67% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
9.93% Insiders
24.93% Mutual Funds
11.43% Other Institutional Investors
39.91% Public Companies and
Individual Investors